Coronavirus disease 2019 (COVID‐19) vaccines: A concise review

Samaranayake, Lakshman Perera; Seneviratne, Chaminda Jayampath; Fakhruddin, Kausar Sadia

The development of a successful vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), the agent of coronavirus disease 2019 (COVID‐19), in an unmatched period of ten months, is a tribute to human ingenuity in the face of a vicious pandemic. A return to pre‐pandemic “normalcy” depends on the successful delivery of the vaccine to a majority (~70%) so as to develop herd immunity critical to arrest the community spread of infection. Vaccination against COVID‐19 is particularly important for dentistry as the dental team works in an environment replete with aerosol‐generating procedures (AGP) that facilitate virus spread. Hence, a COVID‐19 vaccine is likely to be an obligatory requirement for the dental practice, and the latest addition to the extensive list of vaccines required for dental professionals for the safe delivery of dental care. Here, we review the currently available major candidate vaccines against SARS‐CoV‐2 and their benefits and risks. These include the vaccines developed on next‐generation platforms (mRNA, DNA, and viral vector vaccines), and the classic platforms (the live‐attenuated virus, and the protein subunit vaccines) The review concludes with a summary of impending issues and challenges facing the provision of COVID‐19 vaccines for all stakeholders in dentistry.